Table 4 Similar IC 50s were observed in all combination groups regardless of treatment schedule
From: Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
| Â | Normoxia (21% O2) | Potentiation | Hypoxia (N2) | Potentiation |
|---|---|---|---|---|
|  | IC50(μM) | (fold) | IC50(μM) | (fold) |
TH-302 only | 580 | Â | 7.4 | Â |
AZD7762 2 h before TH-302 | 39 | 15 | 0.4 | 19 |
AZD7762 with TH-302 | 34 | 17 | 0.3 | 25 |
AZD7762 0 h after TH-302 | 42 | 14 | 0.5 | 14 |
AZD7762 2 h post TH-302 | 61 | 10 | 0.4 | 19 |
AZD7762 4 h post TH-302 | 42 | 14 | 0.6 | 12 |
AZD7762 6 h post TH-302 | 46 | 13 | 0.6 | 12 |
AZD7762 24 h post TH-302 | 84 | 7 | 0.4 | 19 |